Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMD1 | P17707 | 3/20 | 0.77 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.70 |
| ▸ | PRMT1 | Q99873 | 8/20 | 0.70 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.70 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.66 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10664708 | 0.99 | AMD1 (0.76) | AMD1EZH2DOT1LPRMT1CARM1 | |
| Sulfuric Acid SCHEMBL955704 | 0.95 | AMD1 (0.81) | AMD1EZH2DOT1LPRMT1CARM1 | |
| Sulfuric Acid SCHEMBL955710 | 0.95 | AMD1 (0.81) | AMD1EZH2DOT1LPRMT1CARM1 | |
| SCHEMBL954273 | 0.94 | AMD1 (0.80) | AMD1EZH2DOT1LPRMT1CARM1 | |
| SCHEMBL954272 | 0.94 | AMD1 (0.80) | AMD1EZH2DOT1LPRMT1CARM1 | |
| Water SCHEMBL10665695 | 0.93 | AMD1 (0.79) | AMD1EZH2DOT1LPRMT1CARM1 | |
| SCHEMBL19111327 | 0.90 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL13986400 | 0.90 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL15012484 | 0.89 | AMD1 (0.73) | AMD1EZH2DOT1LPRMT1DPP4 | |
| SCHEMBL952218 | 0.89 | AMD1 (0.73) | AMD1EZH2DOT1LPRMT1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| CN-105163730-A | Methods and compositions for treating demyelinating diseases | PATHOLOGICA LLC | 2015-12-16 | — | — | CN | disclosed |
| EP-2943189-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | Pathologica LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| CN-104997762-A | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA LLC | 2015-10-28 | — | — | CN | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8609734-B2 | Methods of treating pain with MGBG | Pathdogica, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2453886-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | Pathologica, LLC. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | AMD1 6/4885EZH2 1253/4885DOT1L 2184/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | AMD1 6/4885EZH2 1253/4885DOT1L 2184/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | AMD1 269/4885EZH2 11/4885DOT1L 13/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | AMD1 940/4885EZH2 3355/4885DOT1L 4058/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | AMD1 940/4885EZH2 3355/4885DOT1L 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.